Pentamethylcyclopentadienyl rhodium and iridium complexes containing oxinato ligands

The neutral chloro complexes [(η⁵-C₅Me₅)M(η²-NC₉H₆O)Cl] as well as the cationic aqua complexes [(η⁵-C₅Me₅)M(η²-NC₉H₆O)(H₂O)]⁺ (M = Rh, Ir) have been synthesized from the reaction of the dinuclear precursors [(η⁵-C₅Me₅)MCl₂]₂ and 8-hydroxyquinoline. The single crystal X-ray structure analysis of [(η⁵-C₅Me₅)Ir(η²-NC₉H₆O)Cl] reveals for these complexes a piano-stool arrangement with the aromatic ligand, the chelating oxinato ligand and the terminal chloro or aqua ligand surrounding the metal center in a pseudo-tetrahedral fashion.     

A Comparative Analysis of the In Vitro Anticancer Activity of Iridium(III) {η5-C5Me4R} Complexes with Variable R Groups

Piano-stool iridium complexes based on the pentamethylcyclopentadienyl ligand (Cp*) have been intensively investigated as anticancer drug candidates and hold much promise in this setting. A systematic study aimed at outlining the effect of Cp* mono-derivatization on the antiproliferative activity is presented here. Thus, the dinuclear complexes [Ir(η⁵-C₅Me₄R)Cl(μ-Cl)]₂ (R = Me, 1a; R = H, 1b; R = Pr, 1c; R = 4-C₆H₄F, 1d; R = 4-C₆H₄OH, 1e), their 2-phenylpyridyl mononuclear derivatives [Ir(η⁵-C₅Me₄R)(k_N,k_CPhPy)Cl] (2a–d), and the dimethylsulfoxide complex [Ir{η⁵-C₅Me₄(4-C₆H₄OH)}Cl₂(κ_S-Me₂S=O)] (3) were synthesized, structurally characterized, and assessed for their cytotoxicity towards a panel of six human and rodent cancer cell lines (mouse melanoma, B16; rat glioma, C6; breast adenocarcinoma, MCF-7; colorectal carcinoma, SW620 and HCT116; ovarian carcinoma, A2780) and one primary, human fetal lung fibroblast cell line (MRC5). Complexes 2b (R = H) and 2d (4-C₆H₄F) emerged as the most active ones and were selected for further investigation. They did not affect the viability of primary mouse peritoneal cells, and their tumoricidal action arises from the combined influence on cellular proliferation, apoptosis and senescence. The latter is triggered by mitochondrial failure and production of reactive oxygen and nitrogen species.     

Self-assembled chloro-bridged metallo-prismatic cations of the general formula [M6(η-C5Me5)6(μ3-tpt)2(μ-Cl)6] (M = Rh, Ir; tpt = 2,4,6-tri(pyridin-4-yl)-1,3,5-triazine)

Two cationic pentamethylcyclopentadienyl metal-based hexanuclear complexes with trigonal prismatic architecture have been synthesised through a two-step strategy. The dinuclear complexes [M(η⁵- C₅Me₅)(μ-Cl)Cl]₂ (M = rhodium and iridium) react with 2,4,6-tri(pyridin-4-yl)-1,3,5-triazine (tpt) in dichloromethane to give the trinuclear complexes [Rh₃(η⁵-C₅Me₅)₃(μ₃-tpt)Cl₆] (1) and [Ir₃(η⁵-C₅Me₅)₃(μ₃-tpt)Cl₆] (2), respectively. Addition of silver triflate to 1 and 2 in dichloromethane connects two identical triangular panels to form the hexanuclear metallo-prismatic cations [Rh₆(η⁵-C₅Me₅)₆(μ₃-tpt)₂(μ-Cl)₆]⁶⁺ (3) and [Ir₆(η⁵-C₅Me₅)₆(μ₃-tpt)₂(μ-Cl)₆]⁶⁺ (4), respectively. Cations 3 and 4 have been isolated as their triflate salts and characterised by ¹H NMR, IR and UV/visible spectroscopy.     

Ruthenium Complexes with 2-Pyridin-2-yl-1H-benzimidazole as Potential Antimicrobial Agents: Correlation between Chemical Properties and Anti-Biofilm Effects

Antimicrobial resistance is a growing public health concern that requires urgent action. Biofilm-associated resistance to antimicrobials begins at the attachment phase and increases as the biofilms maturate. Hence, interrupting the initial binding process of bacteria to surfaces is essential to effectively prevent biofilm-associated problems. Herein, we have evaluated the antibacterial and anti-biofilm activities of three ruthenium complexes in different oxidation states with 2-pyridin-2-yl-1H-benzimidazole (L₁ = 2,2′-PyBIm): [(η⁶-p-cymene)Ru^IIClL₁]PF₆ (Ru(II) complex), mer-[Ru^IIICl₃(CH₃CN)L₁]·L₁·3H₂O (Ru(III) complex), (H₂L₁)₂[Ru^IIICl₄(CH₃CN)₂]₂[Ru^IVCl₄(CH₃CN)₂]·2Cl·6H₂O (Ru(III/IV) complex). The biological activity of the compounds was screened against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa strains. The results indicated that the anti-biofilm activity of the Ru complexes at concentration of 1 mM was better than that of the ligand alone against the P. aeruginosa PAO1. It means that ligand, in combination with ruthenium ion, shows a synergistic effect. The effect of the Ru complexes on cell surface properties was determined by the contact angle and zeta potential values. The electric and physical properties of the microbial surface are useful tools for the examined aggregation phenomenon and disruption of the adhesion. Considering that intermolecular interactions are important and largely define the functions of compounds, we examined interactions in the crystals of the Ru complexes using the Hirshfeld surface analysis.     

An easy entry to novel early–late oligonuclear transition metal complexes containing π-conjugated systems

Heterotrinuclear Ti–Cu–Ru (5) and heterotetranuclear Ti–Cu–Pt–Fe (7) containing complexes are accessible by using {[Ti](CC^tBu)₂}CuMe (1) ([Ti]=(η⁵-C₅H₄SiMe₃)₂Ti) as key molecule; in 5 and 7, the corresponding early and late transition metal atoms are linked by π-conjugated organic moieties.     

A convenient one-step synthesis of alkenyl-phosphonio complexes of ruthenium(II), rhodium(III) and iridium(III)

Alkenyl-phosphonio complexes of ruthenium(II), rhodium(III) and iridium(III) were prepared by reactions of [(p-cymene)RuCl₂(PPh₃)] or [C_p^*MCl₂(PPh₃)] (M=Rh, Ir; C_p^*=C₅Me₅) with 1-ethynylbenzene and triphenylphosphine in the presence of KPF₆.     

Synthesis,Cytotoxicity, DNA Binding and Apoptosis of Rhein-Phosphonate Derivatives as Antitumor Agents

Several rhein-phosphonate derivatives (5a–c) were synthesized and evaluated for in vitro cytotoxicity against HepG-2, CNE, Spca-2, Hela and Hct-116 cell lines. Some compounds showed relatively high cytotoxicity. Especially compounds 5b exhibited the strongest cytotoxicity against HepG-2 and Spca-2 cells (IC₅₀ was 8.82 and 9.01 μM), respectively. All the synthesized compounds exhibited low cytotoxicity against HUVEC cells. Further experiments proved that 5b could disturb the cell cycle in HepG-2 cells and induce apoptosis. In addition, the binding properties of a model conjugate 5b to DNA were investigated by methods (UV-Vis, fluorescence, CD spectroscopy). Results indicated that 5b showed moderate ability to interact ct-DNA.     

Evaluation of the In Vitro and In Vivo Efficacy of Ruthenium Polypyridyl Compounds against Breast Cancer

The clinical success of cisplatin, carboplatin, and oxaliplatin has sparked the interest of medicinal inorganic chemistry to synthesize and study compounds with non-platinum metal centers. Despite Ru(II)–polypyridyl complexes being widely studied and well established for their antitumor properties, there are not enough in vivo studies to establish the potentiality of this type of compound. Therefore, we report to the best of our knowledge the first in vivo study of Ru(II)–polypyridyl complexes against breast cancer with promising results. In order to conduct our study, we used MCF7 zebrafish xenografts and ruthenium complexes [Ru(bipy)₂(C₁₂H₈N₆-N,N)][CF₃SO₃]₂ Ru1 and [{Ru(bipy)₂}₂(μ-C₁₂H₈N₆-N,N)][CF₃SO₃]₄ Ru2, which were recently developed by our group. Ru1 and Ru2 reduced the tumor size by an average of 30% without causing significant signs of lethality when administered at low doses of 1.25 mg·L⁻¹. Moreover, the in vitro selectivity results were confirmed in vivo against MCF7 breast cancer cells. Surprisingly, this work suggests that both the mono- and the dinuclear Ru(II)–polypyridyl compounds have in vivo potential against breast cancer, since there were no significant differences between both treatments, highlighting Ru1 and Ru2 as promising chemotherapy agents in breast cancer therapy.     

Catalytic properties of Ru-η-C6H6-diphosphine complexes for hydrogenation of benzene in aqueous-organic biphasic system

The influences of pH on the catalytic properties of Ru-η⁶-C₆H₆-diphosphine complex [RuCl(η⁶-C₆H₆)(BISBI)]Cl (1) (BISBI = 2,2′-bis(diphenylphosphinomethyl)-1,1′-biphenyl), [RuCl(η⁶-C₆H₆)(BDPX)]Cl (2) (BDPX = 1,2-bis(diphenylphosphinomethyl)benzene), Ru₂Cl₄(η⁶-C₆H₆)₂(μ₂-BDNA) (3) (BDNA = 1,8-bis(diphenylphosphinomethyl)naphthalene), [RuCl(η⁶-C₆H₆)(BISBI)]BF₄ (4), [RuCl(η⁶-C₆H₆)(BDPX)]BF₄ (5), and [(η⁶-C₆H₆)₂Ru₂Cl₂(μ₂-Cl)(μ₂-BDNA)]BF₄ (6) for the hydrogenation of benzene were investigated in aqueous-organic biphasic system. The hydrogenation of benzene catalyzed by all complexes yielded only cyclohexane. The catalytic results revealed that the stabilities of these complexes were not only closely relative with their compositions or molecular structures but also the pH value of aqueous solution. Complexes 1 and 2 were homogeneous catalysts at pH <5, but complexes 3, 4, 5 and 6 were partly decomposed in the same reaction conditions and played simultaneously the roles of homogeneous and heterogeneous catalysts. When the pH was up to 12, all of six complexes were gradually decomposed to Ru(0) particles. The addition of extra phosphine ligand was favorable to prevent these complexes from decomposing in the catalytic process. The experiment of mercury poisoning and the curve of conversion vs time strongly supported above conclusions.     

Alkyl Chain Growth on a Transition Metal Center: How Does Iron Compare to Ruthenium and Osmium?

Industrial Fischer-Tropsch processes involve the synthesis of hydrocarbons usually on metal surface catalysts. On the other hand, very few homogeneous catalysts are known to perform a Fischer-Tropsch style of reaction. In recent work, we established the catalytic properties of a diruthenium-platinum carbene complex, [(CpRu)₂(μ²-H)(μ²-NHCH₃)(μ³-C)PtCH₃(P(CH₃)₃)₂](CO)_n⁺ with n = 0, 2 and Cp = η⁵-C₅(CH₃)₅, and showed it to react efficiently by initial hydrogen atom transfer followed by methyl transfer to form an alkyl chain on the Ru-center. In particular, the catalytic efficiency was shown to increase after the addition of two CO molecules. As such, this system could be viewed as a potential homogeneous Fischer-Tropsch catalyst. Herein, we have engineered the catalytic center of the catalyst and investigated the reactivity of trimetal carbene complexes of the same type using iron, ruthenium and osmium at the central metal scaffold. The work shows that the reactivity should increase from diosmium to diruthenium to diiron; however, a non-linear trend is observed due to multiple factors contributing to the individual barrier heights. We identified all individual components of these reaction steps in detail and established the difference in reactivity of the various complexes.     

Copper(II) Complexes Containing Natural Flavonoid Pomiferin Show Considerable In Vitro Cytotoxicity and Anti-inflammatory Effects

A series of new heteroleptic copper(II) complexes of the composition [Cu(L)(bpy)]NO₃·2MeOH (1), [Cu(L)(dimebpy)]NO₃·2H₂O (2), [Cu(L)(phen)]NO₃·2MeOH (3), [Cu(L)(bphen)]NO₃·MeOH (4), [Cu(L)(dppz)]NO₃·MeOH (5) was prepared, where HL = 3-(3,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-6-(3-methylbut-2-ene-1-yl)-4H,8H-benzo[1,2-b:3,4-b′]dipyran-4-one, (pomiferin) and bpy = 2,2′-bipyridine, dimebpy = 4,4′-dimethyl-2,2′-bipyridine, phen = 1,10-phenanthroline, bphen = 4,7-diphenyl-1,10-phenanthroline, and dppz = dipyrido[3,2-a:2′,3′-c]phenazine. The complexes were characterized using elemental analysis, infrared and UV/Vis spectroscopies, mass spectrometry, thermal analysis and conductivity measurements. The in vitro cytotoxicity, screened against eight human cancer cell lines (breast adenocarcinoma (MCF-7), osteosarcoma (HOS), lung adenocarcinoma (A549), prostate adenocarcinoma (PC-3), ovarian carcinoma (A2780), cisplatin-resistant ovarian carcinoma (A2780R), colorectal adenocarcinoma (Caco-2) and monocytic leukemia (THP-1), revealed the complexes as effective antiproliferative agents, with the IC₅₀ values of 2.2–13.0 μM for the best performing complexes 3 and 5. All the complexes 1–5 showed the best activity against the A2780R cells (IC₅₀ = 2.2–6.6 μM), and moreover, the complexes demonstrated relatively low toxicity on healthy human hepatocytes, with IC₅₀ > 100 μM. The complexes were evaluated by the Annexin V/propidium iodide apoptosis assay, induction of cell cycle modifications in A2780 cells, production of reactive oxygen species (ROS), perturbation of mitochondrial membrane potential, inhibition of apoptosis and inflammation-related signaling pathways (NF-κB/AP-1 activity, NF-κB translocation, TNF-α secretion), and tested for nuclease mimicking activity. The obtained results revealed the corresponding complexes to be effective antiproliferative and anti-inflammatory agents.     

Synthesis and structural characterization of isomeric monocarbon (η-dicyclopentenyl)-closo-rhodacarboranes stabilized by the agostic bonding interaction

The [7-Me₃N-nido-7-CB₁₀H₁₂] (1), after being treated with two molar equiv. of Proton Sponge, reacts with [(η⁴-C₁₀H₁₂)₂Rh₂(μ-Cl)₂] (2) in benzene–ethanol solution affording two isomeric monocarbon (η-dicyclopentenyl)-closo-rhodacarborane complexes, differing in hapticity of the carbocyclic ligand, viz. [2,2-{(2′,3′-η²):(5′-η¹)-C₁₀H₁₃}-1-(Me₃N)-2,1-closo-RhCB₁₀H₁₀] (3) and [2-{(1′-3′-η³)-C₁₀H₁₃}-1-(Me₃N)-2,1-closo-RhCB₁₀H₁₀] (4). Isomeric compounds 3 and 4 were characterized by analytical, multinuclear NMR spectroscopic data as well as by single-crystal X-ray diffraction study, which revealed the existence of an agostic C–H⋯Rh interaction in both the species.     

Organometallic ruthenium complexes with thiosemicarbazone ligands: Synthesis,structure and cytotoxicity of [(η6-p-cymene)Ru(NS)Cl]+ (NS = 9-anthraldehyde thiosemicarbazones)

A series of half-sandwich arene ruthenium complexes containing bidentate thiosemicarbazone ligands have been synthesized and their biological activity investigated. The compounds have the general formula [(6-p-cymene)Ru(R-ATSC)Cl]X (ATSC = 9-anthraldehyde thiosemicarbazone and R = H, CH₃ and C₆H₅). The crystal structure of [(6-p-cymene) Ru(MeATSC)Cl]Cl have been determined and represents the first structurally characterized arene–ruthenium half-sandwich complex with a thiosemicarbazone ligand. The complexes show good cytotoxic profiles against MCF-7 and MDA-MB-231 (breast adenocarcinoma) as well as HCT 116 and HT-29 (colorectal carcinoma) cell lines.     

Serotonin Promotes Serum Albumin Interaction with the Monomeric Amyloid β Peptide

Prevention of amyloid β peptide (Aβ) deposition via facilitation of Aβ binding to its natural depot, human serum albumin (HSA), is a promising approach to preclude Alzheimer’s disease (AD) onset and progression. Previously, we demonstrated the ability of natural HSA ligands, fatty acids, to improve the affinity of this protein to monomeric Aβ by a factor of 3 (BBRC, 510(2), 248–253). Using plasmon resonance spectroscopy, we show here that another HSA ligand related to AD pathogenesis, serotonin (SRO), increases the affinity of the Aβ monomer to HSA by a factor of 7/17 for Aβ₄₀/Aβ₄₂, respectively. Meanwhile, the structurally homologous SRO precursor, tryptophan (TRP), does not affect HSA’s affinity to monomeric Aβ, despite slowdown of the association and dissociation processes. Crosslinking with glutaraldehyde and dynamic light scattering experiments reveal that, compared with the TRP-induced effects, SRO binding causes more marked changes in the quaternary structure of HSA. Furthermore, molecular docking reveals distinct structural differences between SRO/TRP complexes with HSA. The disintegration of the serotonergic system during AD pathogenesis may contribute to Aβ release from HSA in the central nervous system due to impairment of the SRO-mediated Aβ trapping by HSA.     

Arene ruthenium(II) p-chloroacetophenone phenylthiosemicarbazone complex mediated transfer hydrogenation of ketones

A series of cationic half-sandwich arene ruthenium(II) complexes of general formula [Ru(η⁶-p-cymene)Cl(L)]Cl have been synthesized from the reaction of [Ru(η⁶-p-cymene)Cl₂]₂ with thiosemicarbazone derivatives (L). Characterization of the complexes were accomplished by analytical and spectral (FT-IR, UV–Vis, ¹H NMR) methods. Single crystal structure determination reveals the presence of a pseudooctahedral three-legged piano stool conformation. All the complexes exhibit a quasi-reversible one electron reduction in the range from ?0.75 to ?0.85 V. Further, the catalytic activity of the titled complex has been investigated in the transfer hydrogenation of ketones in the presence of isopropanol/NaOH.     

Synthesis and characterisation of the first examples of four-membered ring ruthenalactam complexes

Reaction of the complexes [RuCl₂(PPh₃)L] (L = η⁶-p-cymene or η⁶-hexamethylbenzene) with N-cyanoacetylurethane [NCCH₂C(O)NHCO₂Et] and tertiary amine base in refluxing methanol gives the first examples of mononuclear complexes containing the four-membered ruthenalactam ring, Ru–C–C(O)–N. The complexes were characterised by ¹H and ³¹P{¹H} NMR spectroscopy and ESI mass spectrometry. A single-crystal X-ray diffraction study on the p-cymene complex showed the four-membered ruthenalactam ring to be planar.     

In Vitro Activity of Copper(II) Complexes,Loaded or Unloaded into a Nanostructured Lipid System,against Mycobacterium tuberculosis

Tuberculosis (TB) is an infectious disease caused mainly by the bacillus Mycobacterium tuberculosis (Mtb), presenting 9.5 million new cases and 1.5 million deaths in 2014. The aim of this study was to evaluate a nanostructured lipid system (NLS) composed of 10% phase oil (cholesterol), 10% surfactant (soy phosphatidylcholine, sodium oleate), and Eumulgin^® HRE 40 ([castor oil polyoxyl-40-hydrogenated] in a proportion of 3:6:8), and an 80% aqueous phase (phosphate buffer pH = 7.4) as a tactic to enhance the in vitro anti-Mtb activity of the copper(II) complexes [CuCl₂(INH)₂]·H₂O (1), [Cu(NCS)₂(INH)₂]·5H₂O (2) and [Cu(NCO)₂(INH)₂]·4H₂O (3). The Cu(II) complex-loaded NLS displayed sizes ranging from 169.5 ± 0.7095 to 211.1 ± 0.8963 nm, polydispersity index (PDI) varying from 0.135 ± 0.0130 to 0.236 ± 0.00100, and zeta potential ranging from −0.00690 ± 0.0896 to −8.43 ± 1.63 mV. Rheological analysis showed that the formulations behave as non-Newtonian fluids of the pseudoplastic and viscoelastic type. Antimycobacterial activities of the free complexes and NLS-loaded complexes against Mtb H₃₇Rv ATCC 27294 were evaluated by the REMA methodology, and the selectivity index (SI) was calculated using the cytotoxicity index (IC₅₀) against Vero (ATCC^® CCL-81), J774A.1 (ATCC^® TIB-67), and MRC-5 (ATCC^® CCL-171) cell lines. The data suggest that the incorporation of the complexes into NLS improved the inhibitory action against Mtb by 52-, 27-, and 4.7-fold and the SI values by 173-, 43-, and 7-fold for the compounds 1, 2 and 3, respectively. The incorporation of the complexes 1, 2 and 3 into the NLS also resulted in a significant decrease of toxicity towards an alternative model (Artemia salina L.). These findings suggest that the NLS may be considered as a platform for incorporation of metallic complexes aimed at the treatment of TB.     

Homoleptic complexes [Ru(L-L)3]2+ (L-L=diphosphine,diarsine)

Homoleptic Ru(II)–diphosphine and Ru(II)–diarsine complexes [Ru(L-L)₃](OTf)₂ (L-L=Me₂P(CH₂)_nPMe₂; n=1, dmpm; n=2, dmpe) and 1,2-C₆H₄(AsMe₂)₂ (diars) have been isolated, in which the Ru(II) state is stabilised to an unprecedented degree, and the crystal structure of [Ru(diars)₃]Cl₂ has been determined.     

Quinolyl-Based PGM Metallarectangles: Antiproliferative Activity,DNA and BSA Protein Interactions,and a Molecular Docking Perspective

The increased success of small metal-containing molecules as pharmaceutical agents has prompted investigations into the pharmacological activity of a different class of metal-based compounds; supramolecular coordination complexes (SCCs). Such complexes have been extensively investigated for their anticancer activity, with many displaying activities comparable or superior to available clinical chemotherapeutic drugs. Here, we evaluated a series of quinoline-containing binuclear complexes and metallarectangles for their in vitro anticancer activity in the hormone receptor positive MCF-7 and triple negative MDA-MB-231 breast cancer cell lines. The preliminary cytotoxic screen, in the MCF-7 cell line, revealed that the ligand (7-chloro-4-(pyridin-4-yl)quinoline, L ) and metallarectangle [{Ir(μ-Cl)(Cp*)}₄(μ- L )₂](OTf)₄ display superior activity to cisplatin, while [{Ru(p-cymene)}₄(μ-η²-η²-C₂O₄)₂(μ- L )₂](OTf)₄ was more potent than cisplatin in the triple-negative MDA-MD-231 cell line. Upon evaluation in a multidose screen, ligand L and metallarectangle [{Ir(μ-Cl)(Cp*)}₄(μ- L )₂](OTf)₄ displayed antiproliferative activity almost two-fold greater than cisplatin in the MCF-7 cell line, while [{Ru(p-cymene)}₄(μ-η²-η²-C₂O₄)₂(μ- L )₂](OTf)₄ was over two-times more active than cisplatin in the MDA-MB-231 cell line. Additionally, using the non-tumorigenic MCF-12 A breast epithelial cell line, the compounds demonstrate increased selectivity toward breast cancer cells over non-tumorigenic cells. Furthermore, investigations into the interactions of ligand L and selected complexes with calf thymus DNA (CT-DNA) and bovine serum albumin (BSA) indicate favourable binding.     

Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90

Inhibition of the molecular chaperone heat shock protein 90 (Hsp90) represents a promising approach for cancer treatment. BIIB021 is a highly potent Hsp90 inhibitor with remarkable anticancer activity; however, its clinical application is limited by lack of potency and response. In this study, we aimed to investigate the impact of replacing the hydrophobic moiety of BIIB021, 4-methoxy-3,5-dimethylpyridine, with various five-membered ring structures on the binding to Hsp90. A focused array of N⁷/N⁹-substituted purines, featuring aromatic and non-aromatic rings, was designed, considering the size of hydrophobic pocket B in Hsp90 to obtain insights into their binding modes within the ATP binding site of Hsp90 in terms of π–π stacking interactions in pocket B as well as outer α-helix 4 configurations. The target molecules were synthesized and evaluated for their Hsp90α inhibitory activity in cell-free assays. Among the tested compounds, the isoxazole derivatives 6b and 6c, and the sole six-membered derivative 14 showed favorable Hsp90α inhibitory activity, with IC₅₀ values of 1.76 µM, 0.203 µM, and 1.00 µM, respectively. Furthermore, compound 14 elicited promising anticancer activity against MCF-7, SK-BR-3, and HCT116 cell lines. The X-ray structures of compounds 4b, 6b, 6c, 8, and 14 bound to the N-terminal domain of Hsp90 were determined in order to understand the obtained results and to acquire additional structural insights, which might enable further optimization of BIIB021.